New Releases from NCBI BookshelfAcalabrutinib for treating chronic lymphocytic leukaemia.Acalabrutinib for treating chronic lymphocytic leukaemia.
Post Content
July 31, 2025
Uncategorized
New Releases from NCBI BookshelfExagamglogene Autotemcel (Casgevy): Therapeutic area: Transfusion-dependent beta thalassemia: Reimbursement Review [Internet].Exagamglogene Autotemcel (Casgevy): Therapeutic area: Transfusion-dependent beta thalassemia: Reimbursement Review [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfBlinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal).Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfTrastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies.Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies.
Post Content
Uncategorized
New Releases from NCBI BookshelfAlternate Level of Care in Canada: Evidence Assessment Report: Health Systems [Internet].Alternate Level of Care in Canada: Evidence Assessment Report: Health Systems [Internet].
Alternate level of care (ALC) is a designation used and applied by clinical staff to the portion of a patient’s
Uncategorized
New Releases from NCBI BookshelfRozanolixizumab (Rystiggo): Indication: For the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive: Reimbursement Recommendation [Internet].Rozanolixizumab (Rystiggo): Indication: For the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that public drug plans reimburse Rystiggo as an add-on therapy for the treatment of adult
Uncategorized
New Releases from NCBI BookshelfPhysician Productivity in Specialty Care: A Scoping Review.Physician Productivity in Specialty Care: A Scoping Review.
The purpose of this report was to review the available evidence on physician productivity measures. This report was requested by
Uncategorized
New Releases from NCBI BookshelfIbrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal).Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfDrugs for Adults With Spinal Muscular Atrophy: A Focused Review and Critical Appraisal of Recent Evidence (2021 to 2025) on Nusinersen and Risdiplam: Drugs [Internet].Drugs for Adults With Spinal Muscular Atrophy: A Focused Review and Critical Appraisal of Recent Evidence (2021 to 2025) on Nusinersen and Risdiplam: Drugs [Internet].
Spinal muscular atrophy (SMA) is a rare genetic condition that affects muscle strength and movement in both children and adults.
Uncategorized
New Releases from NCBI BookshelfGuidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis [Internet].Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis [Internet].
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV
